phospholipase A2 group IIFGenealiases: GIIFsPLA2 · sPLA2-IIF
Q-omics provides the consensus-scored PLA2G2F profile across patient tissues and cancer cell-line models. PLA2G2F expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PLA2G2F is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, PLA2G2F RNA expression shows 10,859 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KIRC, BLCA, and HNSC as cancer lineages where PLA2G2F shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLA2G2F — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLA2G2F survival associations across molecular data types. PLA2G2F RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLA2G2F RNA expression–survival associations across cancer types. High PLA2G2F expression shows unfavorable associations in KIRC, LGG, KIRP, SKCM and ESCA, but favorable associations in BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KIRC as the clearest survival context for PLA2G2F RNA expression.
This table summarizes PLA2G2F tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for PLA2G2F. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLA2G2F shows higher tumor expression in BLCA, LUAD, HNSC, STAD, LUSC and BRCA. The BLCA box plot shows higher PLA2G2F RNA expression in tumor versus normal tissue (log2 FC = +3.675, t-test p < 0.001).
This table shows molecular features associated with PLA2G2F in patient tissues and cancer cell lines. In patient samples, PLA2G2F shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, PLA2G2F RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and URINARY_TRACT.
